Investors.beamtx.com

  1. Home
  2. Investors.beamtx.com

Investor Overview Beam Therapeutics

WEBInitiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024 CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Beam …

Actived: 9 days ago

URL: https://investors.beamtx.com/

Beam Therapeutics Announces Business and Pipeline …

WEBCompany On-track to Submit First IND with BEAM-101 in the Second Half of 2021 Acquisition of Guide Therapeutics Supports Targeting of Diverse Tissues for In …

Category:  Health Go Health

Beam Therapeutics Presents Preclinical Data Highlighting …

WEBSingle Dose of BEAM-301 Restored Clinically Meaningful Endpoints in In Vivo Rodent Disease Models Out to at Least One Year Company Plans to Submit U.S. …

Category:  Health Go Health

Beam Therapeutics Announces Portfolio Prioritization and …

WEBHighest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for …

Category:  Health Go Health

Beam Therapeutics Announces Pipeline and Business …

WEBBEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022 Natural …

Category:  Health Go Health

Beam Therapeutics Announces Preclinical Data …

WEBData to be Presented During an Oral Presentation at the 2021 International HBV Meeting. CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Beam …

Category:  Health Go Health

Beam Announces Agreement for Lilly to Acquire Beam’s …

WEBBeam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026 …

Category:  Health Go Health

Beam Therapeutics Announces First Patient Dosed in …

WEBBEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base …

Category:  Health Go Health

Events Beam Therapeutics

WEB2023 Wells Fargo Securities Healthcare Conference. September 07, 2023 at 10:15 AM EDT.

Category:  Health Go Health

Beam Therapeutics Reports Pipeline Updates and First Quarter …

WEBFocused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth …

Category:  Health Go Health

Pfizer and Beam Enter Exclusive Multi-Target

WEBFour-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid …

Category:  Health Go Health

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 …

WEBAdvancing Pipeline of Wholly Owned Base Editing Therapeutics with Four Development-stage Programs Expanding Investment in a Broad Portfolio of Potential …

Category:  Health Go Health

Beam Therapeutics Presents First In Vivo Data Demonstrating …

WEBCAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines …

Category:  Medicine Go Health

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its …

WEBCAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines …

Category:  Medicine Go Health

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief …

WEBCAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines …

Category:  Medicine Go Health

Beam Therapeutics Highlights Progress Across Base Editing …

WEBFirst Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress …

Category:  Health Go Health

PRECISION GENETIC MEDICINES THROUGH BASE EDITING

WEBCautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of …

Category:  Health Go Health

Beam Therapeutics Presents Preclinical Data Highlighting Utility of

WEBFirst Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease Models …

Category:  Health Go Health

Top Categories

 › Appendicitis

 › Headaches

 › Gout

 › Women's Health

 › Thyroid

 › Sleep

 › Skin

 › Sexual Health

 › Senior Health

 › Pregnancy

 › Oral Health

 › Neurology

 › Migraine

 › Mental Health

 › Men's Health

 › Menopause

 › Medications

 › Lung Conditions

 › Infectious Disease

 › HIV/AIDS

Popular Searched

 › Https my life cvs health

 › Healthy bar food options

 › Woodford co health dept

 › Vivo health products catalog

 › Synthesis health care reviews

 › Age for dependent health coverage

 › Uw health breast imaging

 › Opm open season health plans

 › Dbt perinatal mental health

 › Burrell behavioral health springfield mo referral form

Recently Searched

 › Kidshealth and healthy eating

 › Employee connections novant health

 › Pet health certificate uk requirements

 › Health it consulting companies

 › Baptist health medical group pulmonology

 › Drexel tower health hospital

 › Healthy cheesecake recipes easy

 › Back to school mental health

 › Health psychologist job description

 › California health care foundation sacramento